Familial polycythemia

This phase 3 trial tests whether adding the drug sapablursen to standard treatment helps people with polycythemia vera, a blood disorder causing too many red blood cells. About 250 participants who currently need regular blood removal (phlebotomy) will receive either sapablursen …

This early-phase trial is testing whether adding abemaciclib to the standard drug ruxolitinib is safe and effective for people with myelofibrosis, a type of bone marrow cancer. The study will enroll 18 adults who have been on ruxolitinib for at least 12 weeks. Researchers will mo…

This trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…

This phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …

This early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This early-stage trial is testing an investigational drug called BEBT-507 in adults with polycythemia vera, a condition where the body makes too many red blood cells. The study aims to find a safe dose and see if the drug can help control blood cell levels, potentially reducing t…

This study tests a new drug called flonoltinib maleate in 60 people with polycythemia vera (a condition where the body makes too many red blood cells) who cannot take or no longer respond to standard treatments. The goal is to see if the drug safely reduces red blood cell levels …

This study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can reduce the need for blood transfusions and increase red blood cell levels. The study is in earl…

This early-stage study tests an experimental drug, INCA036978, in about 218 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check the drug's safety and find the best dose, either alone or with standard treatment. Participants must have a l…

This study looks at how well the drug ropeginterferon alfa-2b works and is tolerated by people with polycythemia vera, a rare blood disorder that raises the risk of blood clots and can turn into more serious disease. About 319 adults who need this treatment will be followed for u…

This study tests whether a new pill (gecacitinib) plus a weekly injection (pegylated interferon) can help people with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to bring blood counts back to normal and ease symptoms. Thirty adults wi…

This study tests a new daily pill called JBI-802 in people with certain blood cancers (myeloproliferative neoplasms and MDS/MPN) who have too many platelets. The trial has two phases: first, finding a safe dose in about 30 adults, then checking if it works. Participants take the …

This study tests whether ruxolitinib works better than current standard therapies (hydroxycarbamide or interferon alpha) for people with high-risk polycythemia vera, a blood cancer that increases red blood cells. About 586 adults aged 18 and older with high-risk features will be …

This study follows about 400 people with certain blood cancers (like essential thrombocythemia and myelofibrosis) who are already taking bomedemstat and benefiting from it. The goal is to collect more information on the drug's long-term safety and how well it controls the disease…

This phase 3 trial compares the experimental drug givinostat to the standard drug hydroxyurea in 220 adults with high-risk polycythemia vera, a blood cancer that increases red blood cells and raises clot risk. The study measures how well each drug controls blood counts and spleen…

This phase 3 trial is testing whether direct oral anticoagulants (DOACs) like apixaban or rivaroxaban are better than low-dose aspirin at preventing blood clots in people with JAK2V617F-positive myeloproliferative neoplasms (blood cancers). The study plans to enroll 1308 high-ris…

This study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…

This study tests low-dose methotrexate, a common arthritis drug, in 54 people with three rare blood cancers: polycythemia vera, essential thrombocythemia, and myelofibrosis. Researchers want to see if it can shrink spleens, improve symptoms, and lower blood counts safely. If succ…

This program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. Th…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This study tests whether adding navtemadlin to the standard drug ruxolitinib helps people with myelofibrosis who aren't getting enough benefit from ruxolitinib alone. About 600 adults with myelofibrosis will first take ruxolitinib, then those with a poor response will be randomly…

This study aims to develop a non-invasive method to detect and track fibrosis (scarring) in myelofibrosis, a serious blood disorder. Currently, doctors must perform a bone marrow biopsy to check fibrosis. The researchers will test whether a blood test and a special PET scan can i…

This phase 2 trial tests whether a curcumin supplement (C3 complex with piperine) can reduce inflammation and improve symptoms in people with certain blood disorders, including CCUS, low-risk MDS, and MPNs. Thirty participants will receive either curcumin or a placebo for 12 mont…

This study tests N-Acetylcysteine (N-AC), an antioxidant, in 27 adults with myeloproliferative neoplasms (MPN) like essential thrombocythemia, polycythemia vera, or myelofibrosis. The goal is to find the best dose that safely reduces symptom burden, measured by a symptom score. P…

This phase 2 trial is testing whether the drug ruxolitinib (Jakafi) can reduce symptoms like fatigue and itching in people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 participants will take the pill daily, and researchers will measure symptom …

This study follows about 200 adults with polycythemia vera (a blood disorder) who do not have an enlarged spleen and are starting treatment with ropeginterferon alfa-2b. Researchers will track symptoms, blood cell counts, and side effects over 36 months in real-world clinics. The…

This pilot study tests whether a 12-week nutrition and exercise program is feasible for patients with myeloproliferative neoplasms (MPNs), a group of blood cancers. Thirty participants will take virtual and in-person classes to learn healthier eating and physical activity habits.…

This study looks at a type of immune cell called monocytes in people with certain blood cancers (polycythemia vera, essential thrombocythemia, and myelofibrosis). Researchers will analyze blood samples from 70 newly diagnosed patients to find unique patterns in these cells. The g…

This study examines why some patients with essential thrombocythemia (ET) later develop polycythemia vera (PV), a related blood condition. Researchers will review medical records of 678 adults to identify risk factors for this change and compare outcomes between those who progres…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study is testing a new technique called optical genome mapping (OGM) to find genetic changes in blood cancers like polycythemia vera, essential thrombocythemia, and myelofibrosis. Researchers will compare OGM with standard genetic tests in 300 patients who need a bone marrow…

This study looks at how the immune system reacts to myeloproliferative neoplasms (MPN), a group of blood cancers. Researchers will collect blood and bone marrow samples from 150 adults with or without MPN to find special immune cells (T cells) that recognize and attack MPN cells.…

This study creates a nationwide registry and biobank for children diagnosed with myeloproliferative neoplasms (MPNs)—rare blood cancers that cause overproduction of blood cells. By collecting medical data and blood samples from up to 500 children across Germany, researchers hope …

This study aims to understand exactly how the drug interferon attacks cancer stem cells in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze blood samples from 80 adults to see why some patients respond well while others do not. T…

This study is for adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis who are starting their first treatment. Researchers want to find out why some patients respond well to standard drugs while others do not. They will look at genetic and immune system …

This long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…

This study is looking for better ways to predict blood clots in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will measure specific markers in the blood of 300 participants to see if they can tell who is at higher risk for clots. The goal …

This study looks at how thick the blood is in 160 people with polycythemia (a condition with too many red blood cells). Researchers want to see if thicker blood causes more symptoms like headaches or dizziness, and how it differs between types of polycythemia. No new treatments a…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…

This study aims to uncover inherited (germline) genetic factors that make some people more likely to develop myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze DNA from 313 patients diagnosed at a young age or with a family history of blood ca…